Letters Sitagliptin in patients with type 2 diabetes

Authors’ reply to de Oliveira

BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f3579 (Published 04 June 2013) Cite this as: BMJ 2013;346:f3579
  1. Dean T Eurich, associate professor1
  2. On behalf of S Simpson, C V Asche, A Senthilselvan, F A McAlister, and J K Sandhu-Minhas
  1. 12-040 Li Ka Shing Center for Health Research Innovation, University of Alberta, Edmonton, AB, Canada T6G 2E1
  1. deurich{at}ualberta.ca

In response to de Oliveira’s first point,1 2 we agree that the long term safety of the drug has not been established. However, sitagliptin has been on the market for only about five years, and our study adds to its safety profile because no short term adverse events were noted. Currently, no study can answer the longer term safety of these drugs, but we found no signals to suggest that it was harmful …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe